Characterization of 23S rRNA domain V mutations in gastric biopsy patients from the eastern Amazon

Barile, Katarine Antônia dos Santos; Silva, Artur da Costa da Luiz; Xavier, José Nazareno; Assumpção, Mônica Baraúna de; Corvelo, Tereza Cristina de Oliveira

doi:10.1590/s0074-02762010000300012

Cited by 7 publications

(4 citation statements)

References 29 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, in the Amazon, which is located in northern Brazil, Barile et al (2010) studied the variability of the 23S rRNA gene sequences of 41 isolates from biopsies of patients with gastric pathologies, and identified the A2143G mutation in only 3.3% of cases, while three other mutations previously linked to cases of resistance were detected in 6.4% (G2224A), 12.9% (T2182C) and 61.3% (T2215C) of cases. Furthermore, three other types of mutations that are not characterized by any population were found in 16.1% of cases.…”

Section: Clarithromycinmentioning

confidence: 99%

“…Furthermore, three other types of mutations that are not characterized by any population were found in 16.1% of cases. In addition to the high prevalence of mutations of the 23S rRNA gene of H. pylori strains circulating in the Amazon (AM), genetic variability of these mutations was detected in individuals with gastric diseases (gastritis, peptic ulcer or gastric cancer), demonstrating the need to regionally characterize the profile of these strains to provide correct therapy (6) .…”

Section: Clarithromycinmentioning

confidence: 99%

See 1 more Smart Citation

Drug Resistance in Helicobacter Pylori

Vianna

Ramis

Ramos

et al. 2016

Arq. Gastroenterol.

View full text Add to dashboard Cite

show abstract

Section: Clarithromycinmentioning

confidence: 99%

Section: Clarithromycinmentioning

confidence: 99%

Drug Resistance in Helicobacter Pylori

Vianna

Ramis

Ramos

et al. 2016

Arq. Gastroenterol.

View full text Add to dashboard Cite

show abstract

“…In contrast, the A2143G mutation occurs in only 23% of resistant strains in Eastern countries [31] . This suggests that clarithromycin point mutations may be geographically distinct between Eastern and Western countries and new point mutations have appeared in South America [33] . Clarithromycin resistance is also different depending on the area.…”

Section: Current Antibiotic Resistance In Worldwidementioning

confidence: 99%

Antibiotic treatment forHelicobacter pylori: Is the end coming?

Kim

Choi

Chung

2015

WJGPT

View full text Add to dashboard Cite

Infection with the Gram-negative pathogen Helicobacter pylori (H. pylori ) has been associated with gastroduodenal disease and the importance of H. pylori eradication is underscored by its designation as a group I carcinogen. The standard triple therapy consists of a proton pump inhibitor, amoxicillin and clarithromycin, although many other regimens are used, including quadruple, sequential and concomitant therapy regimens supplemented with metronidazole, clarithromycin and levofloxacin. Despite these efforts, current therapeutic regimens lack efficacy in eradication due to antibiotic resistance, drug compliance and antibiotic degradation by the acidic stomach environment. Core tip: This article reviews the recent literature describing antibiotic resistance and trends in Helicobacter pylori (H. pylori ) treatment. As there is no effective conventional therapy, new treatments are being developed and bismuth quadruple, sequential, concomitant therapies are recommended as a first-line regimen in regions with high levels of clarithromycin resistance. Quinolones have also been used for H. pylori treatment, although the cure rate has gradually reduced with this approach. New therapeutic directions include probiotic supplementation, tailored therapy, novel agents, and nanotechnology.

show abstract

“…The mutation at position 2143 (A→G) of the 23S rRNA gene has also been predominantly detected in other studies 4 , 12 . However, a large geographic variation can be observed, and an uneven distribution is possible even within a single country, highlighting the importance of characterizing the regional profiles of strains to provide a correct therapy 13 , 14 .…”

Section: Discussionmentioning

confidence: 99%

The interplay between mutations in cagA, 23S rRNA, gyrA and drug resistance in Helicobacter pylori

Vianna¹,

Ramis²,

Ramos³

et al. 2018

Rev. Inst. Med. trop. S. Paulo

View full text Add to dashboard Cite

In this study, we evaluated the mutations of Helicobacter pylori associated with resistance to clarithromycin and levofloxacin. Furthermore, based on the proposed interaction between antimicrobial resistance and pathogenicity, we correlated the mutation profiles of the strains with the presence of the pathogenicity gene cagA. We analyzed 80 gastric biopsy specimens from H. pylori-infected patients for point mutations in the 23S rRNA gene region and in the gyrA gene, which are related to clarithromycin and levofloxacin resistance, respectively, and investigated the presence of the cagA gene in these strains. We observed that in the assayed biopsies, 8.7% (7/80) had mutations in the 23S rRNA gene region at positions 2143 and 2142, while 22.5% (18/80) had mutations in gyrA at codons 87 and 91. Moreover, absence of the CagA-EPIYA pathogenicity factor was observed in 68% (17/25) of resistant samples. The knowledge of the local profile of antimicrobial resistance and the complex interplay involving resistance and pathogenicity can contribute to an appropriate clinical approach.

show abstract

Characterization of 23S rRNA domain V mutations in gastric biopsy patients from the eastern Amazon

Cited by 7 publications

References 29 publications

Drug Resistance in Helicobacter Pylori

Drug Resistance in Helicobacter Pylori

Antibiotic treatment forHelicobacter pylori: Is the end coming?

The interplay between mutations in cagA, 23S rRNA, gyrA and drug resistance in Helicobacter pylori

Contact Info

Product

Resources

About